Sugi Predict

Sugi Predict / Targets / CCND3

CCND3

G1/S-specific cyclin-D3 · P30281 · CCND3 on Sugi Atlas →

73,922 patent compounds predicted against CCND3, 45,588 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL189662 SCHEMBL189662 1.00 20/20
SCHEMBL189897 SCHEMBL189897 0.53 15/20
SCHEMBL190547 SCHEMBL190547 0.61 14/20
Palbociclib Palbociclib (SCHEMBL462630) 1.00 13/20
SCHEMBL660300 SCHEMBL660300 0.66 13/20
SCHEMBL190132 SCHEMBL190132 0.62 13/20
SCHEMBL660950 SCHEMBL660950 0.68 12/20
SCHEMBL188528 SCHEMBL188528 0.60 12/20
SCHEMBL188565 SCHEMBL188565 0.49 12/20
SCHEMBL660218 SCHEMBL660218 0.73 11/20
SCHEMBL659714 SCHEMBL659714 0.72 11/20
SCHEMBL659547 SCHEMBL659547 0.72 11/20
SCHEMBL660413 SCHEMBL660413 0.67 11/20
SCHEMBL660855 SCHEMBL660855 0.65 11/20
SCHEMBL659387 SCHEMBL659387 0.64 11/20
SCHEMBL659837 SCHEMBL659837 0.63 11/20
SCHEMBL610952 SCHEMBL610952 0.48 11/20
SCHEMBL189169 SCHEMBL189169 0.55 10/20
SCHEMBL189845 SCHEMBL189845 0.49 10/20
SCHEMBL343214 SCHEMBL343214 0.59 9/20

Clinical trials — most relevant to CCND3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma PHASE2COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI PHASE2COMPLETED
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma PHASE1/PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets PHASE1UNKNOWN
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Erlotinib in Treating Patients With Barrett Esophagus PHASE1UNKNOWN
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma PHASE1COMPLETED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCND3 binder may also engage these)

ProteinNameSimilarity
Q3MHH5 — 1.000 Q3MHH5 →
P30282 — 1.000 P30282 →
P48961 — 1.000 P48961 →
P25322 — 0.986 P25322 →
Q64HP0 — 0.986 Q64HP0 →
Q0P5D3 — 0.985 Q0P5D3 →
CCND2 G1/S-specific cyclin-D2 0.984 landscape →
Q2KI22 — 0.983 Q2KI22 →
Q8WNW2 — 0.983 Q8WNW2 →
CCND1 G1/S-specific cyclin-D1 0.981 landscape →
Q04827 — 0.981 Q04827 →
Q5R6J5 — 0.981 Q5R6J5 →
P30280 — 0.981 P30280 →
P39948 — 0.981 P39948 →
P53782 — 0.980 P53782 →
Q90459 — 0.979 Q90459 →
P49706 — 0.978 P49706 →
P55169 — 0.977 P55169 →
Q9D995 — 0.973 Q9D995 →
Q32NM1 — 0.971 Q32NM1 →
Q52QT8 — 0.970 Q52QT8 →
P50755 — 0.970 P50755 →
Q8N815 — 0.970 Q8N815 →
Q16589 — 0.969 Q16589 →
CCNE1 G1/S-specific cyclin-E1 0.968 landscape →
Q5E9I1 — 0.967 Q5E9I1 →
Q8N1B3 — 0.964 Q8N1B3 →
Q8IV13 — 0.964 Q8IV13 →
P47794 — 0.964 P47794 →
P51959 — 0.964 P51959 →